- Global Pharma News & Resources

Increase in demand for therapeutics for cancer treatment drives the growth of CAR-T Cell Therapy Market global sales are expected to grow at a CAGR of 15% through 2032 | insightSLICE

The global CAR-T Cell Therapy market size was estimated to be US$ 1.63 billion in 2021 and is expected grow at a CAGR of 15% between 2023 to 2032.

CAR T Cell Therapy stands for Chimeric Antigen Receptor T cell therapy. It is a recombinant T cell-based anti-cancer treatment. The genetically altered T cells act against the target cells via an immunological response. CAR T cells continue to display cytotoxic properties and replicate indefinitely which eventually causes targeted cell death. Due to their capacity to provide long-lasting therapeutic results, CAR T cell therapy has become a ground-breaking technology, especially for cancer treatment.

Access the sample report:

Global CAR-T Cell Therapy Market Key Segments:

By Product Type

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Lisocabtagene Maraleucel
  • Idecabtagene Vicleucel
  • Others

By Indication

  • Acute Lymphocytic Leukaemia
  • Diffuse Large B-cell lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Multiple Myeloma
  • Others

By End

  • Hospitals
  • Cancer Treatment Centers

By Geography

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Extensive R&D ventures have been set up by large global corporations which are also looking for monotherapy or combination drug-based CAT T cell approaches. Clinical trials for various anti-cancer drugs and therapies are on the rise which is expected to enable CAR T cell therapy to enter clinical trials quickly.

This is considered a precision medicine showing significant results against cancer cells, and therefore several companies have started investing in the CAR T cells therapy market.

The pharmaceutical industry is very interested in them due to their innovative mode of action and their specificity against hematologic malignancies. Novartis AG. was the pioneer company in this type of technology and currently holds a big share of this experimental market.

The key players of the Global CAR-T Cell Therapy Market are:

Novartis AG (Kymriah), Yescarta (axicabtagene), Tecartus (brexucabtagene), Kite Pharma Inc., (a Gilead subsidiary), and Bristol-Myers Squibb (breyanzi) are leading companies involved in the CAR T cell therapy market.

Read more about the report inclusions:

Driving factors for CAR-T Cell Therapy Market

Large pharmaceutical companies are rushing to invest in CAR T cell research and development. As the cancer treatment sector is proposed to become the biggest revenue generator for the healthcare industry, cancer R&D is seeing increased funding. Several strategic partnerships between pharma companies and research organizations have come up in recent years to develop novel CAR T cell therapies.

The rising prevalence of cancers, especially hematologic malignancies has given a boost to CAR T cell-based treatment alternatives. Rising demands for alternatives to chemotherapy and radiotherapy have increased the desire for immunotherapy-based approaches like CAR T cells. CAR T cell therapies have also seen an uptick owing to huge investments by companies and increased public adoption.

Rise of CAR T cell therapy in hematologic cancer treatments:

Acute lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), multiple myeloma (MM), mantle cell lymphoma (MCL), have seen beneficial effects from the use of CAR T cell therapies. This technology is also expected to help other hematologic cancers or indications as research is being done. The next phase of cancer research will translate into higher efficiency and better results for CAR T cell therapy.

Lymphoma, leukaemia, and multiple myeloma-based CAR T cell therapies have received approval from regulatory agencies for their profound effects. New developments like monotherapy-based tools and techniques are also awaiting approvals for patients at advanced stages.

CAR T cell therapy has been significantly utilized against lymphoma having a high number of approvals and robust sales. The current Lymphoma specific treatments are expected to grow as technology gets standardized and more companies to enter this sector.

Regional performance of CAR-T Cell Therapy Market

North America has the biggest CAR T cell therapy market in the world. The prominent drivers for the large share of CAR T cell therapy in this region are due to improved healthcare technology, higher per capita income, faster approval, and early adoption of such technologies.

As most of the companies and laboratories involved in this particular research are present in the USA, they see a quicker dispensation of newer CAR T cell therapies than the rest of the world. Apart from North America, CAR T cell-based cancer treatments have seen a better adoption across the Asia-Pacific region as well.

Related reports:

Global Immunoglobulin Market:

Global Hyperlipidemia Drugs Market:

Limitations of the technology

Despite being effective in treating haematological cancers, CAR T cell therapy currently faces obstacles in treating solid tumours. To make CAR T an effective treatment for solid tumours, scientists are constantly looking for appropriate markers and pathways for targeting.

Several different solid tumours have upregulation of the protein OR2H1, according to a new analysis. It is not expected to be anything significant but soon we can see new targets and increased target specificity against solid tumours. This in turn will also translate into better CAT T cell-based solutions for solid tissue cancers.

Several challenges that need to be addressed regarding CAR T cell therapies are still being researched. However, even with their current limitations, investors, clinicians, and researchers have a very positive outlook for this technology.

Reduction of the safety issues arising from non-specific or cross-reactivity is the primary concern for companies and scientists. CAR T cell therapy is also being assessed for its role in viral diseases like HIV, autoimmune disorders, and other cell disorders which will amplify the potential growth of this technology.

Proceed to purchase:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 08-Nov-2022